Table 1.
Comparison of 212Pb-RIT Targeting HER1- and HER2-Positive Tumor Xenografts
| Vehicle | Target | Median Survival (Days) |
|---|---|---|
| None | None | 20 |
| Trastuzumab | HER2 | 182 |
| Cetuximab | HER1 | 147 |
| Panitumumab | HER1 | >293 |
| HuIgG | None | 29 |
A pilot study was performed to compare the therapeutic efficacy of 212Pb-panitumumab to 212Pb-labeled trastuzumab and cetuximab. Athymic mice (n = 10) bearing 3-day i.p. LS-174T tumor xenografts were injected with 10 μCi of each of the 212Pb-labeled mAb. Additional groups included those that received no treatment and those that were injected with 10 μCi of the nonspecific control, 212Pb-HuIgG.